SAN DIEGO—Miguel Regueiro, MD, the chief of the Digestive Disease Institute and a professor of medicine at Cleveland Clinic, in Ohio, sat down with Gastroenterology & Endoscopy News at DDW 2025 to discuss his favorite abstracts on inflammatory bowel disease presented at the conference.

“There were a number of hot abstracts in IBD, too many to go through now, but I decided to pick out some that I thought were of particular interest,” Dr. Regueiro said. 

The studies he identified include a look at risankizumab (Skyrizi, AbbVie) versus optimized dosing of ustekinumab, the effect of seton placement on perianal fistula outcomes, delayed remission with advanced therapies, and novel TL1A nanobody and TL1A/interleukin-23 bispecific nanobody therapies for IBD.   

—GEN Staff

Dr. Regueiro reported no relevant financial disclosures.